Effect of erythropoietin on neutrophil chemiluminescence in hemodialyzed patients

Shang Der Shieh, Kuo Cheng Lu, Pauling Chu, May Chun Gou, Yuh Feng Lin, Yu Chung Chen, Tai Pin Shyh

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Erythropoietin (EPO) has been used widely for correcting anemia in hemodialyzed (HD) patients. Enhancement of phagocytic function during EPO treatment of HD patients has been studied, but no data have been available on the effect of EPO on neutrophil chemiluminescence (CL) after challenge with phorbol myristate acetate (PMA). CL was measured in prehemodialysis whole blood samples from 15 stabilized patients and 15 normal healthy control subjects (C) after challenge with PMA. Before EPO treatment, CL was noted to be significantly higher in HD patients than in C, which changed significantly after 5 weeks of treatment (Rx) and continued for 13 weeks of Rx. There was a significant increase in hematocrit in these HD patients after 5 weeks that persisted until the 13th week. It was concluded that there is a significant decrease in whole blood CL in response to challenge with PMA during correction of anemia in HD patients treated with EPO. This study demonstrated that EPO could decrease enhanced PMA-activated reactive oxygen metabolite production and suggested that this decrease may protect against tissue damage, including red blood cell hemolysis in the uremic milieu.

Original languageEnglish
JournalASAIO Transactions
Volume37
Issue number3
Publication statusPublished - Jul 1991
Externally publishedYes

Fingerprint

Chemiluminescence
Erythropoietin
Luminescence
Neutrophils
Tetradecanoylphorbol Acetate
Blood
Anemia
Metabolites
Cells
Tissue
Hemolysis
Hematocrit
Oxygen
Healthy Volunteers
Therapeutics
Erythrocytes

ASJC Scopus subject areas

  • Biophysics

Cite this

Shieh, S. D., Lu, K. C., Chu, P., Gou, M. C., Lin, Y. F., Chen, Y. C., & Shyh, T. P. (1991). Effect of erythropoietin on neutrophil chemiluminescence in hemodialyzed patients. ASAIO Transactions, 37(3).

Effect of erythropoietin on neutrophil chemiluminescence in hemodialyzed patients. / Shieh, Shang Der; Lu, Kuo Cheng; Chu, Pauling; Gou, May Chun; Lin, Yuh Feng; Chen, Yu Chung; Shyh, Tai Pin.

In: ASAIO Transactions, Vol. 37, No. 3, 07.1991.

Research output: Contribution to journalArticle

Shieh, SD, Lu, KC, Chu, P, Gou, MC, Lin, YF, Chen, YC & Shyh, TP 1991, 'Effect of erythropoietin on neutrophil chemiluminescence in hemodialyzed patients', ASAIO Transactions, vol. 37, no. 3.
Shieh, Shang Der ; Lu, Kuo Cheng ; Chu, Pauling ; Gou, May Chun ; Lin, Yuh Feng ; Chen, Yu Chung ; Shyh, Tai Pin. / Effect of erythropoietin on neutrophil chemiluminescence in hemodialyzed patients. In: ASAIO Transactions. 1991 ; Vol. 37, No. 3.
@article{f2ed797330c84becb84f89b18a076fc5,
title = "Effect of erythropoietin on neutrophil chemiluminescence in hemodialyzed patients",
abstract = "Erythropoietin (EPO) has been used widely for correcting anemia in hemodialyzed (HD) patients. Enhancement of phagocytic function during EPO treatment of HD patients has been studied, but no data have been available on the effect of EPO on neutrophil chemiluminescence (CL) after challenge with phorbol myristate acetate (PMA). CL was measured in prehemodialysis whole blood samples from 15 stabilized patients and 15 normal healthy control subjects (C) after challenge with PMA. Before EPO treatment, CL was noted to be significantly higher in HD patients than in C, which changed significantly after 5 weeks of treatment (Rx) and continued for 13 weeks of Rx. There was a significant increase in hematocrit in these HD patients after 5 weeks that persisted until the 13th week. It was concluded that there is a significant decrease in whole blood CL in response to challenge with PMA during correction of anemia in HD patients treated with EPO. This study demonstrated that EPO could decrease enhanced PMA-activated reactive oxygen metabolite production and suggested that this decrease may protect against tissue damage, including red blood cell hemolysis in the uremic milieu.",
author = "Shieh, {Shang Der} and Lu, {Kuo Cheng} and Pauling Chu and Gou, {May Chun} and Lin, {Yuh Feng} and Chen, {Yu Chung} and Shyh, {Tai Pin}",
year = "1991",
month = "7",
language = "English",
volume = "37",
journal = "ASAIO Journal",
issn = "1058-2916",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Effect of erythropoietin on neutrophil chemiluminescence in hemodialyzed patients

AU - Shieh, Shang Der

AU - Lu, Kuo Cheng

AU - Chu, Pauling

AU - Gou, May Chun

AU - Lin, Yuh Feng

AU - Chen, Yu Chung

AU - Shyh, Tai Pin

PY - 1991/7

Y1 - 1991/7

N2 - Erythropoietin (EPO) has been used widely for correcting anemia in hemodialyzed (HD) patients. Enhancement of phagocytic function during EPO treatment of HD patients has been studied, but no data have been available on the effect of EPO on neutrophil chemiluminescence (CL) after challenge with phorbol myristate acetate (PMA). CL was measured in prehemodialysis whole blood samples from 15 stabilized patients and 15 normal healthy control subjects (C) after challenge with PMA. Before EPO treatment, CL was noted to be significantly higher in HD patients than in C, which changed significantly after 5 weeks of treatment (Rx) and continued for 13 weeks of Rx. There was a significant increase in hematocrit in these HD patients after 5 weeks that persisted until the 13th week. It was concluded that there is a significant decrease in whole blood CL in response to challenge with PMA during correction of anemia in HD patients treated with EPO. This study demonstrated that EPO could decrease enhanced PMA-activated reactive oxygen metabolite production and suggested that this decrease may protect against tissue damage, including red blood cell hemolysis in the uremic milieu.

AB - Erythropoietin (EPO) has been used widely for correcting anemia in hemodialyzed (HD) patients. Enhancement of phagocytic function during EPO treatment of HD patients has been studied, but no data have been available on the effect of EPO on neutrophil chemiluminescence (CL) after challenge with phorbol myristate acetate (PMA). CL was measured in prehemodialysis whole blood samples from 15 stabilized patients and 15 normal healthy control subjects (C) after challenge with PMA. Before EPO treatment, CL was noted to be significantly higher in HD patients than in C, which changed significantly after 5 weeks of treatment (Rx) and continued for 13 weeks of Rx. There was a significant increase in hematocrit in these HD patients after 5 weeks that persisted until the 13th week. It was concluded that there is a significant decrease in whole blood CL in response to challenge with PMA during correction of anemia in HD patients treated with EPO. This study demonstrated that EPO could decrease enhanced PMA-activated reactive oxygen metabolite production and suggested that this decrease may protect against tissue damage, including red blood cell hemolysis in the uremic milieu.

UR - http://www.scopus.com/inward/record.url?scp=0026182306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026182306&partnerID=8YFLogxK

M3 - Article

C2 - 1751104

AN - SCOPUS:0026182306

VL - 37

JO - ASAIO Journal

JF - ASAIO Journal

SN - 1058-2916

IS - 3

ER -